Robinson Sarah E, Findlay Andrew R, Li Shan, Wang Feng, Schiava Marianela, Daw Jil, Diaz-Manera Jordi, Chou Tsui-Fen, Weihl Conrad C
From the Department of Neurology (S.E.R., A.R.F., J.D., C.W.), Washington University in St. Louis, MO; John Walton Muscular Dystrophy Research Centre (S.L., F.W., M.S., J.D.-M.), Newcastle University and Newcastle Hospitals NHS Foundation Trusts, United Kingdom; and Division of Biology and Biological Engineering (T.-F.C.), California Institute of Technology, Pasadena.
Neurol Genet. 2024 Sep 12;10(5):e200191. doi: 10.1212/NXG.0000000000200191. eCollection 2024 Oct.
Multisystem proteinopathy-1 (MSP1) is a late onset disease with >50 pathogenic variants in p97/VCP. MSP1 patients have multiple phenotypes that include inclusion body myopathy, Paget disease of the bone, amyotrophic lateral sclerosis, and frontotemporal dementia. There have been no clear genotype-phenotype correlations. We sought to identify genotype-phenotype correlations and associate these with VCP intrinsic ATPase activity.
Patients with MSP1 were identified from the literature and the Cure VCP patient registry. Age at onset and at loss of ambulation were collated. VCP intrinsic ATPase activity was evaluated from recombinant purified protein.
Among the 5 most common pathogenic variants in MSP1 patients, R155C patients had the earliest average age at onset (38.15 ± 9.78). This correlated with higher ATPase activity. Evaluation of 5 variants confirmed an inverse correlation between age at onset and ATPase activity (r = -0.94, = 0.01).
Previous studies have reported that VCP pathogenic variants are "hyperactive." Whether this elevation in VCP ATPase activity is relevant to disease is unclear. Our study supports that in vitro VCP activity correlates with disease onset and may guide the prognosis of patients with rare or unreported variants. Moreover, it suggests that inhibition of VCP ATPase activity in MSP1 may be therapeutic.
多系统蛋白病-1(MSP1)是一种迟发性疾病,其p97/VCP基因存在超过50种致病变异。MSP1患者有多种表型,包括包涵体肌病、骨佩吉特病、肌萎缩侧索硬化症和额颞叶痴呆。目前尚无明确的基因型-表型相关性。我们试图确定基因型-表型相关性,并将其与VCP内在ATP酶活性联系起来。
从文献和“治愈VCP”患者登记处识别出MSP1患者。整理发病年龄和丧失行走能力的年龄。从重组纯化蛋白评估VCP内在ATP酶活性。
在MSP1患者中5种最常见的致病变异中,R155C患者的平均发病年龄最早(38.15±9.78)。这与较高的ATP酶活性相关。对5种变异的评估证实发病年龄与ATP酶活性呈负相关(r = -0.94,P = 0.01)。
先前的研究报道VCP致病变异是“高活性的”。VCP ATP酶活性的这种升高是否与疾病相关尚不清楚。我们的研究支持体外VCP活性与疾病发病相关,并可能指导罕见或未报道变异患者的预后。此外,这表明抑制MSP1中VCP ATP酶活性可能具有治疗作用。